Aptose Stock Analysis

APTO -  USA Stock  

USD 3.40  0.07  2.02%

The modest gains experienced by current holders of Aptose Bioscns could raise concerns from institutional investors as the firm it trading at a share price of 3.40 on 1,165,500 in volume. The company executives have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in May. The stock standard deviation of daily returns for 90 days investing horizon is currently 9.68. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Aptose Bioscns partners.
Please continue to Trending Equities.

Search Stock Analysis 

The Aptose Bioscns stock analysis report makes it easy to digest most publicly released information about Aptose Bioscns and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Aptose stock analysis module also helps to analyze the Aptose Bioscns price relationship with some important fundamental indicators such as market cap and management efficiency.

Aptose Stock Analysis Notes

About 55.0% of the company shares are held by institutions such as insurance companies. The book value of Aptose Bioscns was presently reported as 1.34. The company recorded a loss per share of 0.68. Aptose Bioscns had not issued any dividends in recent years. The entity had 1:12 split on the 6th of October 2014. Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada. Aptose Bioscns operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people. For more info on Aptose Bioscns please contact Roger Korman at 647 479 9828 or go to http://www.aptose.com.

Aptose Bioscns Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Aptose Bioscns' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Aptose Bioscns or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Aptose Bioscns has very high historical volatility over the last 90 days
Aptose Bioscns has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 19.72 M. Net Loss for the year was (55.24 M) with profit before overhead, payroll, taxes, and interest of 0.
Aptose Bioscns currently holds about 122.39 M in cash with (33.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38.
Aptose Bioscns has a frail financial position based on the latest SEC disclosures

Aptose Bioscns Upcoming and Recent Events

Earnings reports are used by Aptose Bioscns to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Aptose Bioscns previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report3rd of August 2021
Next Earnings Report9th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End22nd of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Aptose Largest EPS Surprises

Earnings surprises can significantly impact Aptose Bioscns' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Aptose Bioscns SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Aptose Bioscns prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Aptose Bioscns investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Aptose Bioscns specific information freely available to individual and institutional investors to make a timely investment decision.
11th of June 2021
Financial Statements and Exhibits. Regulation FD Disclosure
1st of June 2021
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders
4th of May 2021
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Results of Operations and Financial Condition
26th of March 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
23rd of March 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
16th of March 2021
Financial Statements and Exhibits. Regulation FD Disclosure
17th of February 2021
Unclassified Corporate Event
16th of February 2021
Unclassified Corporate Event

Aptose Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Aptose Bioscns is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aptose Bioscns backward and forwards among themselves. Aptose Bioscns' institutional investor refers to the entity that pools money to purchase Aptose Bioscns' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Orbimed Advisors LlcCommon SharesM48 M
Drw Securities LlcCommon SharesM47.7 M
Nantahala Capital Management LlcCommon Shares7.7 M46.2 M
Cormorant Asset Management LpCommon SharesM23.9 M
First Light Asset Management LlcCommon Shares3.1 M18.5 M
Pictet Asset Management LtdCommon Shares2.7 M16.1 M
Eventide Asset Management LlcCommon Shares2.3 M13.7 M
Note, although Aptose Bioscns' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Aptose Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 300.51 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aptose Bioscns's market, we take the total number of its shares issued and multiply it by Aptose Bioscns's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Aptose Profitablity

Aptose Bioscns' profitability indicators refer to fundamental financial ratios that showcase Aptose Bioscns' ability to generate income relative to its revenue or operating costs. If, let's say, Aptose Bioscns is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Aptose Bioscns' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Aptose Bioscns' profitability requires more research than a typical breakdown of Aptose Bioscns' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(0.50) (0.54) 
Return on Average Equity(0.53) (0.58) 
Return on Invested Capital(2.42) (2.48) 
Return on Sales 36.85  36.64 

Management Efficiency

The entity has return on total asset (ROA) of (30.74) % which means that it has lost $30.74 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (51.91) %, meaning that it created substantial loss on money invested by shareholders. Aptose Bioscns management efficiency ratios could be used to measure how well aptose bioscns manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Average Assets is estimated to slide to -0.54. The value of Return on Average Equity is estimated to slide to -0.58. Aptose Bioscns Total Assets are quite stable at the moment as compared to the past year. The company's current value of Total Assets is estimated at 136.23 Million. Current Assets is expected to rise to about 135 M this year, although the value of Return on Average Assets will most likely fall to (0.54) .
Last ReportedProjected for 2021
Book Value per Share 1.45  1.29 
Enterprise Value over EBIT(5.00) (5.39) 
Enterprise Value over EBITDA(5.32) (5.46) 
Price to Book Value 3.27  3.90 
Tangible Assets Book Value per Share 1.54  1.53 
Enterprise Value290.7 M313.6 M
Tangible Asset Value126.3 M136.2 M

Technical Drivers

As of the 19th of June, Aptose Bioscns shows the Risk Adjusted Performance of 0.0221, mean deviation of 4.07, and Downside Deviation of 6.5. Aptose Bioscns technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Aptose Bioscns, which can be compared to its rivals. Please confirm Aptose Bioscns variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Aptose Bioscns is priced correctly, providing market reflects its regular price of 3.4 per share. Given that Aptose Bioscns has jensen alpha of 0.1834, we suggest you to validate Aptose Bioscns's prevailing market performance to make sure the company can sustain itself at a future point.

Aptose Bioscns Price Movement Analysis

The output start index for this execution was thirty-nine with a total number of output elements of twenty-two. Aptose Bioscns Triple Exponential Moving Average indicator shows smoothing effect of Aptose Bioscns price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average. View also all equity analysis or get more info about triple exponential moving average overlap studies indicator.

Aptose Bioscns Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aptose Bioscns insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aptose Bioscns' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aptose Bioscns insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bejar Rafael over three months ago via Macroaxis 
Acquisition by Bejar Rafael of 343000 shares of Aptose Biosciences subject to Rule 16b-3
Warren Whitehead over three months ago via Macroaxis 
Exercise or conversion by Warren Whitehead of 20000 shares of Aptose Biosciences subject to Rule 16b-3
Jotin Marango over six months ago via Macroaxis 
Sale by Jotin Marango of 20946 shares of Aptose Biosciences
Warren Whitehead over six months ago via Macroaxis 
Exercise or conversion by Warren Whitehead of 7000 shares of Aptose Biosciences subject to Rule 16b-3
Jotin Marango over a year ago via Macroaxis 
Acquisition by Jotin Marango of 80000 shares of Aptose Biosciences subject to Rule 16b-3
William Rice over a year ago via Macroaxis 
Purchase by William Rice of 3400 shares of Aptose Biosciences
Carol Ashe over a year ago via Macroaxis 
Acquisition by Carol Ashe of 50000 shares of Aptose Biosciences subject to Rule 16b-3
Bejar Rafael over a year ago via Macroaxis 
Acquisition by Bejar Rafael of 200000 shares of Aptose Biosciences subject to Rule 16b-3
Bejar Rafael over a year ago via Macroaxis 
Acquisition by Bejar Rafael of 400000 shares of Aptose Biosciences subject to Rule 16b-3
Denis Burger over a year ago via Macroaxis 
Aptose Biosciences exotic insider transaction detected
Denis Burger over a year ago via Macroaxis 
Acquisition by Denis Burger of 40000 shares of Aptose Biosciences subject to Rule 16b-3
Marango Jotin over a year ago via Macroaxis 
Acquisition by Marango Jotin of 320000 shares of Aptose Biosciences subject to Rule 16b-3

Aptose Bioscns Predictive Daily Indicators

Aptose Bioscns intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Aptose Bioscns stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Aptose Bioscns Forecast Models

Aptose Bioscns time-series forecasting models is one of many Aptose Bioscns' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aptose Bioscns' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Aptose Bioscns Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Aptose Bioscns stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Aptose shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Aptose Bioscns. By using and applying Aptose Stock analysis, traders can create a robust methodology for identifying Aptose entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin 37.44  37.22 
Gross Margin 0.90  0.89 
Profit Margin 36.63  36.42 
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1ab clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806 and CG-806, which are in Phase 1ab clinical trial for the treatment of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkins lymphomas, as well as relapsedrefractory acute myeloid leukemia. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Current Aptose Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Aptose analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Aptose analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
10.4Strong Buy5Odds
Aptose Bioscns current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Aptose analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Aptose stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Aptose Bioscns, talking to its executives and customers, or listening to Aptose conference calls.
Aptose Analyst Advice Details

Aptose Stock Analysis Indicators

Aptose Bioscns stock analysis indicators help investors evaluate how Aptose Bioscns stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Aptose Bioscns shares will generate the highest return on investment. By understating and applying Aptose Bioscns stock analysis, traders can identify Aptose Bioscns position entry and exit signals to maximize returns.
Quick Ratio17.97
Fifty Two Week Low3.3300
Shares Short Prior Month2.42M
Average Daily Volume Last 10 Day3.78M
Average Daily Volume In Three Month4.45M
Shares Percent Shares Out4.15%
Short Percent Of Float4.17%
Forward Price Earnings-6.30
Float Shares69.06M
Fifty Two Week High7.3000
Enterprise Value To Ebitda-6.59
Fifty Day Average5.0297
Two Hundred Day Average4.7415
Please continue to Trending Equities. Note that the Aptose Bioscns information on this page should be used as a complementary analysis to other Aptose Bioscns' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Aptose Bioscns Stock analysis

When running Aptose Bioscns price analysis, check to measure Aptose Bioscns' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aptose Bioscns is operating at the current time. Most of Aptose Bioscns' value examination focuses on studying past and present price action to predict the probability of Aptose Bioscns' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Aptose Bioscns' price. Additionally, you may evaluate how the addition of Aptose Bioscns to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Transaction History
View history of all your transactions and understand their impact on performance
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
CEO Directory
Screen CEOs from public companies around the world
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
The market value of Aptose Bioscns is measured differently than its book value, which is the value of Aptose that is recorded on the company's balance sheet. Investors also form their own opinion of Aptose Bioscns' value that differs from its market value or its book value, called intrinsic value, which is Aptose Bioscns' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptose Bioscns' market value can be influenced by many factors that don't directly affect Aptose Bioscns underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptose Bioscns' value and its price as these two are different measures arrived at by different means. Investors typically determine Aptose Bioscns value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptose Bioscns' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.